In the first quarter, the net profit of the biopharmaceutical sector on the Science and Technology Innovation Board doubled, and the concentration of leading companies repurchasing and increasing holdings conveyed confidence.

Net profit doubled, buyback trend surged, and the long-term value of the biopharmaceutical sector on the science and technology innovation board has been recognized. Data shows that in the first quarter of 2026, a total of 119 biopharmaceutical companies on the science and technology innovation board achieved operating income of 32.714 billion yuan, a year-on-year increase of 15.21%; achieving a net profit of 3.141 billion yuan, a year-on-year increase of 109.26%. The industry's prosperity continues to rise, and the quality of profits has significantly improved. Looking at the subdivision track, the acceleration of innovative drug research and development results, the commercialization volume superimposed with BD going global, jointly driving the sector to reach a profit inflection point, and the prosperity level is transmitted to upstream CXO and other supporting links, enhancing the synergistic effect of the industry chain; high-end medical devices and consumables rely on overseas markets to open up new growth space; with valuation at historical lows, many leading companies are actively repurchasing and increasing their holdings, releasing a signal of optimism for long-term development.